Eko Health closes $41M Series D round
Eko Health, a digital health company focused on heart and lung disease, closed a $41 million Series D funding round.
The company sells digital stethoscopes that block out background noise and have digital displays with additional information such a patient's heart rate. The company said in a release it plans to use the capital to expand its artificial intelligence-enabled disease detection platform.
Read more: Top digital health funding: Natural Cycles, Transcend, Plenful
Venture capital firms ARTIS Ventures, Highland Capital Partners, NTTVC and Questa Capital participated in the round.
The funding brings the company’s total raised to $167 million.
Sword Health raises $130M increasing valuation to $3B
$100 million of the funding is secondary, which are shares purchased from existing employee shareholders. The amount will go toward providing liquidity to current and former employees as well as early investors. The remaining $30 million is new capital to be used for growth. Read more.
Sware secures $6M
Sware, a software validation company focused on life sciences and medical technology companies, said it secured $6 million in a Series B funding round.
Venture capital firm First Analysis led the round. Existing investors LRVHealth, New Stack Ventures and Insight Partners also participated.
Related: LRVHealth launches $200M digital health fund
Sware sells software that makes it easier companies to validate software for data integrity, reliability and patient safety. The company said in a release the round will be used to invest in AI and expand its sales teams.
The round brings the company’s total raised to $26 million.
Eyebot closes $6M seed round
Eyebot, a point-of-sale eye prescription technology company, said it secured a $6 million seed funding round.
Venture capital firms AlleyCorp and Ubiquity Ventures led the round. Venture capital firms Susa Ventures, Village Global, Baukunst, Ravelin and Spacecadet also participated.
Eyebot is the latest in a series of digital health-focused investments from AlleyCorp. Other portfolio companies for the New York City-based firm include women’s health company Maven, physician enablement company Pearl Health and digital staffing company Nomad Health.
Eyebot sells technology aimed at quickening the pace of self-serve vision testing it says can be completed in 90 seconds.
